News

Scientific news
2 Jul 2020

Of the 614 cell lines studied, 7% closely corresponded to a different type of cancer than that thought to give rise to the cell line.

The Genome Data Science Laboratory at IRB Barcelona has drawn up a reference list of 366 cell lines in which the genetic pattern corresponds to the type of tumour that they intend to model.

The work shows that studies using the cell lines on this reference list have a greater discovery rate, and has been published in the journal Science Advances.

 

Scientific news
<p>After APP cleavage at the neuronal membrane, Aβ protein self-assembles into 4 or 8 copies adopting an arrangement allowing passage of water and ions (in red) and thus disrupting ion cell homeostasis © Benjamin Bardiaux.</p>
26 Jun 2020

Researchers led by Natàlia Carulla find that specific amyloid-beta (Aβ) protein ensembles have the capacity to disrupt the membrane of neurons, causing their death.

The results have been published in the journal Nature communications.

Scientific news
<p>DNA lesions. Credit: Petra Korlevic</p>
25 Jun 2020

DNA damage caused by chemical mutagens is not repaired immediately and can create more genetic diversity in tumours, as lesions pass on unrepaired over several rounds of cell division.

A study by the Liver Cancer Evolution Consortium explores the evolution of tumours after chemical damage, offering interesting insights into how mutational processes work.

The work has been published in the journal Nature.

 

Institutional news
<p>Representatives of investment funds on the signing of the Series A Ona. Francesc Posas, Emilià Pola, Joël Jean-Mairet, Clara Campàs,Salvador Aznar-Benitah, Valerie Vanhooren and Montserrat Vendrell.</p>
16 Jun 2020

Ona Therapeutics, a spin-off from IRB Barcelona and ICREA, was founded by researchers Salvador Aznar-Benitah and Valerie Vanhooren in 2019. The company focuses its activity on the development of a new medicine for the treatment of metastatic cancer.

The venture capital funding round has been headed by Asabys Partners, through its Sabadell Asabys division, and has involved the participation of Alta Life Sciences, Ysios Capital, FundPlus (Belgium) and BPI France (France)

This is the largest private funding round closed for a start-up in Spain.

Scientific news
2 Jun 2020

A role of colibactin-producing E. coli in carcinogenesis.

Institutional news
29 May 2020

Iproteos, one of the 5 spin-offs launched by IRB Barcelona, focuses on the development of third-generation drugs for diseases such as schizophrenia, epilepsy, and atherosclerosis.

Its proprietary technology allows faster research processes to identify new drugs and produce novel molecules.

The new company Accure Therapeutics starts up with €7.6 M of investment, which will allow the development of its product portfolio and the takeover of Iproteos and Bionure.

Institutional news
22 May 2020

The Center for Genomic Regulation (CRG), the National Center for Genomic Analysis (CNAG-CRG), part of CRG, the Institute for Research in Biomedicine (IRB Barcelona) and the Institute for Bioengineering of Catalonia (IBEC) have analysed more than 20,000 samples to date using the PCR technique. In this regard, 17,547 samples have been tested at the CRG node and 5,248 at the PCB node.

The analyses are part of the Orfeu Programme, the mass screening initiative driven by the Government of Catalonia. As of today, the public health system in Catalonia can carry out up to 17,000 PCR tests every day. This number does not include the capacity of the Orfeu Programme, which can process up to...

Scientific news
19 May 2020

The Chemical Checker provides processed, harmonized and ready-to-use bioactivity information on more than 1M small molecules

The tool, developed by the Structural Bioinformatics and Network Biology lab at IRB Barcelona, has been published in Nature Biotechnology.

 

Scientific news
<p>Immunofluorescence of a mouse mammary gland duct (IRB Barcelona)</p>
18 May 2020

Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.

The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.

 

Scientific news
<p>Tumour heterogeneity: cancer stem cells (green) and differentiated cells (in red). IRB Barcelona.</p>
12 May 2020

The Colorectal Cancer Lab at IRB Barcelona identifies the capacity to synthesize proteins (or biosynthetic capacity) as a key property for the regenerative potential of colon cancer cells.

Published in Cell Stem Cell, the study proposes a new therapeutic focus for the scientific community and the pharmaceutical industry to explore.